KANSAS CITY, Mo.--(BUSINESS WIRE)--In a Markov cost-effectiveness model, a comparison of the long-term economic outcomes associated with COPAXONE® (glatiramer acetate injection), and Tysabri® (natalizumab) combined with symptom management versus symptom management alone demonstrated that COPAXONE® was less costly and more effective over a patient’s lifetime than Tysabri® for relapsing-remitting multiple sclerosis (RRMS). Results, announced today at the 10th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) congress in Dublin, Ireland, incorporate Tysabri® in an analysis of an updated Markov model previously published in the Journal of Managed Care Pharmacy in April 2007.
